Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Point32Health | Vyjuvek (Beramagene Geperpavec-Svdt) | New policy |
| Aug 2, 2026 | Point32Health | Vyjuvek (Beramagene Geperpavec-Svdt) | New policy |
| Aug 2, 2026 | Point32Health | Vyepti (eptinezumab-jjmr) | New policy |
| Aug 2, 2026 | Point32Health | Vyepti (eptinezumab-jjmr) | New policy |
| Aug 2, 2026 | Point32Health | Vyalev (foscarbidopa/foslevodopa) | New policy |
| Aug 2, 2026 | Point32Health | Viscosupplementation for Osteoarthritis | New policy |
| Aug 2, 2026 | Point32Health | Vimizim (elosulfase alfa) | New policy |
| Aug 2, 2026 | Point32Health | Viltepso (viltolarsen) | New policy |
| Aug 2, 2026 | Point32Health | Viltepso (viltolarsen) | New policy |
| Aug 2, 2026 | Point32Health | Veopoz (pozelimab-bbfg) | New policy |
| Aug 2, 2026 | Point32Health | Uplizna (inebilizumab-cdon) | New policy |
| Aug 2, 2026 | Point32Health | Uplizna (inebilizumab-cdon) | New policy |
| Aug 2, 2026 | Point32Health | Unified Medical Policies | New policy |
| Aug 2, 2026 | Point32Health | Tzield (teplizumab-mzwv) | New policy |
| Aug 2, 2026 | Point32Health | Tzield (teplizumab-mzwv) | New policy |
| Aug 2, 2026 | Point32Health | Trastuzumab Products | New policy |
| Aug 2, 2026 | Point32Health | Tezspire (tezepelumab-ekko) | New policy |
| Aug 2, 2026 | Point32Health | Tezspire (tezepelumab-ekko) | New policy |
| Aug 2, 2026 | Point32Health | Tezspire (tezepelumab-ekko) | New policy |
| Aug 2, 2026 | Point32Health | Tezspire (tezepelumab-ekko) | New policy |
| Aug 2, 2026 | Point32Health | Testosterone Replacement Therapies | New policy |
| Aug 2, 2026 | Point32Health | Tepezza (teprotumumab-trbw) | New policy |
| Aug 2, 2026 | Point32Health | Tepezza (teprotumumab-trbw) | New policy |
| Aug 2, 2026 | Point32Health | Tecvayli (teclistamab-cqyv) | New policy |
| Aug 2, 2026 | Point32Health | Tecvayli (teclistamab-cqyv) | New policy |
| Aug 2, 2026 | Point32Health | Tecelra (afamitresgene autoleucel) | New policy |
| Aug 2, 2026 | Point32Health | Tecelra (afamitresgene autoleucel) | New policy |
| Aug 2, 2026 | Point32Health | Tecartus (brexucabtagene autoleucel) | New policy |
| Aug 2, 2026 | Point32Health | Tecartus (brexucabtagene autoleucel) | New policy |
| Aug 2, 2026 | Point32Health | Targeted Immunomodulators – Skilled Administration | New policy |
| Aug 2, 2026 | Point32Health | Targeted Immunomodulators Skilled administration | New policy |
| Aug 2, 2026 | Point32Health | Targeted Immunomodulators Skilled Administration | New policy |
| Aug 2, 2026 | Point32Health | Targeted Immunomodulators Skilled Administration | New policy |
| Aug 2, 2026 | Point32Health | Talvey (talquetamab-tgvs) | New policy |
| Aug 2, 2026 | Point32Health | Talvey (talquetamab-tgvs) | New policy |
| Aug 2, 2026 | Point32Health | Takhzyro (lanadelumab-flyo) | New policy |
| Aug 2, 2026 | Point32Health | Synagis (palivizumab) | New policy |
| Aug 2, 2026 | Point32Health | Syfovre (pegcetacoplan injection) | New policy |
| Aug 2, 2026 | Point32Health | Syfovre (pegcetacoplan injection) | New policy |
| Aug 2, 2026 | Point32Health | Sublocade (buprenorphine extendedrelease) | New policy |
| Aug 2, 2026 | Point32Health | Spravato (esketamine) | New policy |
| Aug 2, 2026 | Point32Health | Spravato (esketamine) | New policy |
| Aug 2, 2026 | Point32Health | Spravato (esketamine) | New policy |
| Aug 2, 2026 | Point32Health | Spinraza (nusinersen) | New policy |
| Aug 2, 2026 | Point32Health | Spinraza (nusinersen) | New policy |
| Aug 2, 2026 | Point32Health | Spevigo spesolimab-sbzo) | New policy |
| Aug 2, 2026 | Point32Health | Spevigo spesolimab-sbzo) | New policy |
| Aug 2, 2026 | Point32Health | Spevigo (spesolimab-sbzo) | New policy |
| Aug 2, 2026 | Point32Health | Somatostatin Analogs for Oncology Indications | New policy |
| Aug 2, 2026 | Point32Health | Somatostatin Analogs for Oncology Indications | New policy |